Filing Details
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) filed a Form 8-K with the Securities and Exchange Commission on November 09, 2026, disclosing a material event.
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) filed a Form 8-K with the Securities and Exchange Commission on November 09, 2026, disclosing a material event.

At publication ·
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) · 8k filed
At a glance
Viridian Therapeutics, Inc.\DE (NASDAQ:VRDN) filed a Form 8-K with the Securities and Exchange Commission on November 09, 2026, disclosing a material event.
Viridian Therapeutics, Inc.\DE's stock currently trades at $28.49 with a market capitalization of $2.6B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Viridian Therapeutics, Inc.\DE's stock.
All SEC filings for Viridian Therapeutics, Inc.\DE are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VRDN Stock Page
Browse all filings on our VRDN SEC filings page.
Public companies like Viridian Therapeutics, Inc.\DE file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · VRDN
$31.44
Up: +$1.32 · +4.38%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
earnings ·